CPRI heads into the week with an unusual split: options traders have turned sharply more cautious just as short sellers are quietly trimming positions.
The standout this week is in options. The put/call ratio has jumped to 0.43, nearly three standard deviations above its 20-day average of 0.24 — the most defensive options posture the stock has seen outside a brief spike in the past year. That's not a marginal drift; it's a clear step-change. For three weeks the PCR sat in a tight band around 0.14–0.23, then doubled almost overnight on June 19–22. Something has made options traders materially more interested in downside protection, with the stock having already lost 7.8% on the week to close at $19.15.
Short interest tells a less aggressive story. Shorts have actually been reducing exposure — the short position has pulled back to 8.3% of the free float, down about 11% over the past month after peaking near 9.5% of float in mid-May. The borrow market backs this up: cost to borrow runs at just 0.46%, well below any level that would signal a contested trade, and availability is plentiful at roughly 500% of current short interest, meaning lenders have far more shares available than are currently being borrowed. Nothing in the lending market suggests pressure building from the short side. The divergence between a short book that's shrinking and an options book that's hedging is the clearest tension in the setup right now.
On the Street, the direction of travel has been mostly downward on price targets. Following the late-May earnings print, UBS, BofA, Wells Fargo, and Telsey Advisory all lowered targets while keeping neutral-to-hold ratings, settling in the $20–$21 range. JPMorgan held its Overweight but cut from $31 to $29, and BTIG reiterated Buy at $30. The mean target sits around $25.70 — representing roughly 34% implied upside from current levels — but the majority of the Street appears comfortable staying on the sidelines at neutral. The bull case rests on brand rehabilitation at Michael Kors and Versace alongside an ongoing buyback program; the bear case centers on twelve consecutive quarters of Michael Kors sales declines, a challenging macro backdrop for accessible luxury, and debt levels that limit financial flexibility. The PE multiple at 8.7x and EV/EBITDA near 10.8x reflect a stock priced for recovery that hasn't yet arrived.
The insider picture is worth noting. June 16–17 saw CEO John Idol and the Chief Legal Officer sell shares in the open market — combined proceeds of roughly $600,000 — alongside awards of restricted stock. These were post-award sales consistent with tax withholding rather than a change in conviction, and the 90-day net insider position is actually positive at around 293,000 shares. Separately, Greenlight Capital held 4.9 million shares as of March-end, a notable active-manager presence, while Dimensional Fund Advisors added roughly 558,000 shares through late May.
Earnings are next due on August 7. The most recent print on May 27 produced a 6.7% one-day gain, though the stock faded back to flat over the following five days. The print before that, in late May 2026, moved the stock down 6.8% on the day. Neither reaction has been clean or durable. The next print will again test whether management can offer any credible narrative on Michael Kors stabilisation — and whether the options hedging building this week reflects genuine concern about that answer or simply broader apparel-sector nerves, with peers BIRK and ONON each down more than 9–12% on the week.
The widening gap between a shrinking short position and a suddenly elevated options PCR is the tension worth watching into August.
See the live data behind this article on ORTEX.
Open CPRI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
